Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Bgl7.0
Beta-Glucans – Forschung
Hilft wahrscheinlich
121 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Beta-Glucans scheint in 14 von 16 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2003–2026 mit einer typischen Studiengröße von 129 Teilnehmenden.
Basierend auf 121 Studien · 24 Meta-Analysen · 69 RCTs · 16,146 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
14geholfen2unklar· 105 weitere ohne bewertete Effektdaten
Nach Outcome
Cholesterol & lipids
Hilft wahrscheinlich58 Studien
Glucose & metabolic
Hilft vermutlich23 Studien
Weight management
Hilft wahrscheinlich18 Studien
Immune supportVerstärkte Immunantwort und weniger Infektionen · 2-4 weeks
58 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200320142026
1HbA1c reductionMeta-Analysen=2,685 · very large study2023
Einfach gesagt: Galactomannans were the most effective dietary fiber for reducing the levels of HbA1c, fasting blood glucose, triglycerides, and LDL cholesterol in patients with type 2 diabetes.
Juhász AE et al. · The American journal of clinical nutrition (2023)
Galactomannans had the highest effect on reducing the levels of HbA1c (SUCRA: 92.33%) and fasting blood glucose (SUCRA: 85.92%).
With regard to fasting insulin level, HOMA-IR, β-glucans (SUCRA: 73.45%), and psyllium (SUCRA: 96.67%) were the most effective interventions.
Galactomannans were ranked first in reducing the levels of triglycerides (SUCRA: 82.77%) and LDL cholesterol (SUCRA: 86.56%).
2LDL cholesterol reductionMeta-Analysen=1,731 · large study2024
Einfach gesagt: Conclusions: Oat-based products may reduce TC and LDL-C, but have little effect on TG, HDL-C, and major cardiovascular events in patients with dyslipidemia.
Li A et al. · Food & function (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Pooled estimates showed that oat-based products may result in a large reduction in LDL-C (WMD, -0.24 mmol L-1; 95% CI: -0.33, -0.15) (moderate certainty) and TC (WMD, -0.32 mmol L-1; 95% CI: -0.48, -0.17) (moderate certainty).
Compared to other diets (mainly other cereals), oat-based products probably reduce the level of LDL-C (WMD, -0.17 mmol L-1; 95% CI: -0.25, -0.08) (moderate certainty) and TC (WMD, -0.21 mmol L-1; 95% CI: -0.30, -0.12) (moderate certainty).
Both groups showed that oat-based products had little effect on HDL-C and TG (moderate certainty).
3Safety and tolerability of beta-glucan in cancer patientsSystematische Übersichtn=1,650 · large study2021
Einfach gesagt: It was observed that the administration of β-glucan is safe and well-tolerated.
Steimbach L et al. · Clinical nutrition (Edinburgh, Scotland) (2021)
It was observed that the administration of β-glucan is safe and well-tolerated.
Most of the trials pointed that concomitant administration of β-glucan with chemo or radiotherapy reduced the immune depression caused by such treatments and/or accelerated the recovery of white blood cells counts.
However, some articles also commented that no statistical difference was encountered between β-glucan treated vs. control groups, which gives a controversial conclusion about the β-glucan effects.
4Total cholesterol reductionMeta-Analysen=1,120 · large study2021
Einfach gesagt: In conclusion, β-glucan can significantly reduce risk factors like TC and LDL-cholesterol for CVD in mildly hypercholesterolaemic individuals; furthermore, it appears that the effects of food matrices with both 'solid products' and 'liquid products' where β-glucan was incorporated into were ranked as the best way to exert its beneficial properties, while 'liquid' and 'solid' products were ranked as the second and third positions, respectively.
Xu D et al. · The British journal of nutrition (2021)
After conducting a comprehensive search in Web of Science, PubMed, Scopus and Cochrane Library, a total of twenty-one randomised controlled trials involving 1120 participants were identified to measure the pooled effect.
There was evidence for modest unexplained heterogeneity in the meta-analysis.
5Total cholesterol reductionMeta-Analysen=927 · large study2022
Einfach gesagt: This meta-analysis supports the health benefits of oat beta-glucan, especially for its cholesterol-lowering features, although it has some inevitable limitations.
Yu J et al. · Nutrients (2022)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The results were presented with the weighted mean difference (WMD) with a 95% CI.
Overall, oat beta-glucan supplementation significantly reduced levels of TC (pooled WMD = -0.24 mmol/L; 95%CI: -0.28 to -0.20 mmol/L), LDL-c (pooled WMD = -0.27 mmol/L; 95%CI: -0.35 to -0.20 mmol/L).
Furthermore, beta-glucan consumption did not show significant effects on TG (pooled WMD = -0.04 mmol/L; 95%CI: -0.13 to 0.05 mmol/L), HDL-c (pooled WMD = 0.00 mmol/L; 95%CI: -0.05 to 0.05 mmol/L).
Einfach gesagt: Adding ≥3 g OBG/d to the diet reduces LDL and total cholesterol by 0.25 mmol/L and 0.30 mmol/L, respectively, without changing HDL cholesterol or triglycerides.
Whitehead A, Beck EJ, Tosh S, Wolever TM · The American journal of clinical nutrition (2014)
Spürbar Nutzen
← SchlechterKein EffektBesser →
A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control.
OBG in doses of ≥3 g/d reduced low-density lipoprotein (LDL) and total cholesterol relative to control by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) and 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001), respectively.
LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol, and there was a significantly greater effect for both LDL and total cholesterol in subjects with diabetes.
Einfach gesagt: Higher consumption of whole oats and oat bran, but not oat or barley beta-glucan extracts, are associated with lower HbA1c, fasting glucose and fasting insulin of T2D, hyperlipidaemic and overweight subjects, especially people with T2D, which supports the need for clinical trials to evaluate the potential role of oats in approaching to the management of glycemic control and insulin sensitivity of diabetes or metabolic syndrome subjects.
He LX et al. · Food & function (2016)
The intake of oats and beta-glucan extracted from oats were effective in decreasing fasting glucose (P = 0.007, I(2) = 91%) and fasting insulin of T2D (P < 0.001, I(2) = 0%) and tented to lower HbA1c (P = 0.09, I(2) = 92%).
Compared with the control, oat intake resulted in a greater decrease in fasting glucose and insulin of subjects (P < 0.05), but beta-glucan extract intake did not.
10Clinical outcomes and quality of lifeSystematische Übersichtn=45 · small study2025
Einfach gesagt: However, the evidence is mixed across supplement types, and further research is needed to determine the most effective and safe approaches.
Scafuri L et al. · Nutrients (2025)
Curcumin studies presented mixed results.
Silymarin showed potential for hepatoprotective effects.
Conclusions: These findings highlight the potential of specific dietary supplements to improve various aspects of breast cancer care.
12Fasting glucose concentrationMeta-Analysen=603 · large study2015
Einfach gesagt: In conclusion, there was not a significant overall effect of beta-glucan intake on improvements of fasting glucose and insulin concentrations in hypercholesterolemic subjects.
Zou Y et al. · International journal of food sciences and nutrition (2015)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Summary estimates of weighted mean differences (WMD) and 95% confidence interval was 0.05 mmol/L (-0.11, 0.02) for fasting glucose concentration and 0.75 pmol/L (-1.82, 3.32) for fasting insulin concentrations.
Twelve trials with a total of 603 subjects were included in the meta-analysis.
Beta-glucan consumption did not significantly affect measures of glycemic control.
Einfach gesagt: MinDoses for glucose iAUC for high-MW, medium-MW and low-MW OBG, respectively, were estimated to be 0.2 g, 2.2 g and 3.2 g per 30 g avCHO; MinDoses for glucose iPeak were less than those for iAUC.
Noronha JC et al. · European journal of clinical nutrition (2023)
Results were expressed as ratio-of-means (RoM) with 95% confidence intervals (CIs).
MinDose was defined as the dose at which the upper 95% CI of the regression line cut the line of no effect (i.e., RoM = 1).
MinDoses for glucose iAUC for high-MW, medium-MW and low-MW OBG, respectively, were estimated to be 0.2 g, 2.2 g and 3.2 g per 30 g avCHO; MinDoses for glucose iPeak were less than those for iAUC.
Einfach gesagt: OBG reduced glucose iAUC and iPeak by 23% (0.77 [0.74, 0.81]) and 28% (0.72 [0.64, 0.76]) and insulin by 22% (0.78 [0.72, 0.85]) and 24% (0.76 [0.65, 0.88]), respectively.
Zurbau A et al. · European journal of clinical nutrition (2021)
Groß Nutzen
← SchlechterKein EffektBesser →
Data were pooled using generic inverse-variance with random-effects model and expressed as ratio-of-means with [95% CIs].
OBG reduced glucose iAUC and iPeak by 23% (0.77 [0.74, 0.81]) and 28% (0.72 [0.64, 0.76]) and insulin by 22% (0.78 [0.72, 0.85]) and 24% (0.76 [0.65, 0.88]), respectively.
OBG molecular-weight >300 kg/mol significantly reduced glucose iAUC and iPeak, whereas molecular-weight <300 kg/mol did not.
16Efficacy and safety of commercial beta-glucan productsSystematische Übersichtn=33 · small study2020
Einfach gesagt: Commercial beta-glucan products were studied in a number of RCTs whose results can be considered only as preliminary, as they used small number of participants and surrogate outcomes.
Markovina N et al. · Clinical nutrition (Edinburgh, Scotland) (2020)
Commercial beta-glucan products were studied in a number of RCTs whose results can be considered only as preliminary, as they used small number of participants and surrogate outcomes.
The quality of many studies was poor and further research and trials on bigger population should be performed before a final conclusion can be made.
Einfach gesagt: Dietary OSIs resulted in lowered levels of blood lipids and improvements in anthropometric parameters among participants with predominantly mild metabolic disturbances, regardless of dietary background or control.
Llanaj E et al. · European journal of nutrition (2022)
The majority of included RCTs (81.1%) had some concerns for risk of bias.
Dietary OSIs resulted in lowered levels of blood lipids and improvements in anthropometric parameters among participants with predominantly mild metabolic disturbances, regardless of dietary background or control.
Further high-quality trials are warranted to establish the role of OSIs on blood pressure, glucose homeostasis and inflammation markers.
Einfach gesagt: KEY TEACHING POINTS: • Dietary fiber intake is associated with lower body weight in epidemiologic studies. • Most acute fiber treatments (61%) did not enhance satiety. • Most acute fiber treatments (78%) did not reduce food intake. • Neither fiber type nor fiber dose were related to satiety response or food intake.
Clark MJ et al. · Journal of the American College of Nutrition (2013)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
The percentage of treatments that significantly reduced subjective appetite rating compared with the control was 39%.
The percentage that significantly reduced food or energy intake was 22%.
The satiety-enhancing effects of β-glucan, lupin kernel fiber, rye bran, whole grain rye, or a mixed high-fiber diet were supported in more than one publication.